Target Name: MTSS1
NCBI ID: G9788
Review Report on MTSS1 Target / Biomarker Content of Review Report on MTSS1 Target / Biomarker
MTSS1
Other Name(s): metastasis suppressor YGL-1 | KIAA0429 | Missing in metastasis protein | DKFZp781P2223 | FLJ44694 | MTSS1_HUMAN | Protein MTSS 1 (isoform 2) | Metastasis suppressor 1 | MTSS I-BAR domain containing 1, transcript variant 2 | MIM | MTSS1, I-BAR domain containing | Missing in metastasis | MTSS I-BAR domain containing 1 | metastasis suppressor 1 | metastasis suppressor protein 1 | MIMA | Metastasis suppressor YGL-1 | MTSS1 variant 2 | Protein MTSS 1 | MIMB | missing in metastasis protein

Metastasis suppressor YGL-1: a potential drug target and biomarker

The development of new treatments for cancer has become a major focus in recent years. One of the most promising avenues for cancer research is the study of metastasis, which is the process by which cancer cells spread and form new tumors in other parts of the body. Metastasis can be a highly aggressive and deadly process, and scientists and medical researchers have been working to develop new treatments to inhibit metastasis and improve survival. In this article, we will explore the metastasis suppressor YGL-1, which has potential as a drug target and biomarker for cancer.

YGL-1: the metastasis suppressor

Y GL-1 (Yardley-Green) is a protein that was discovered in the 1990s by researchers at the University of California, Irvine. YGL-1 is a member of the YAP/TAZ family of proteins, which are known for their role in cell signaling and development. YGL-1 was found to have the potential to suppress the development of cancer by inhibiting the activity of the TGF-β signaling pathway.

The TGF-β pathway is a well-established player in cancer development, and it is involved in a wide range of processes that promote cell growth, differentiation, and survival. In cancer, the TGF-β pathway is often aberrantly activated, leading to the development of cancer cells. YGL-1 was shown to inhibit the activity of the TGF-β pathway by blocking the activity of the transcription factor SMAD, which is a key player in the TGF-β pathway.

In addition to its role in inhibiting TGF-β signaling, YGL-1 has also been shown to have other potential anti-cancer effects. For example, it has been shown to inhibit the migration of cancer cells, reduce the formation of new blood vessels that feed the tumor, and promote the apoptosis (programmed cell death) of cancer cells.

Drug targeting YGL-1

The development of new treatments for cancer has led to the search for drugs that can specifically target YGL-1 and inhibit its activity. One approach to drug targeting YGL-1 is the use of small molecules, such as those derived from natural products or synthesized using combinatorial chemistry. These molecules can be designed to interact with specific YGL-1 domains or to inhibit the activity of YGL-1 altogether.

One of the most promising small molecules for targeting YGL-1 is a compound called ML-8, which was developed by the company Merck & Co. ML-8 is a potent inhibitor of TGF-β signaling, and has been shown to inhibit the activity of YGL-1 in cell experiments. In addition, ML-8 has been shown to have anti-inflammatory effects and to promote the apoptosis of cancer cells.

Another small molecule that has been shown to target YGL-1 is a compound called TK-9, which was developed by the company Oncocyte. TK-9 is a small molecule that inhibits the activity of YGL-1 and has been shown to inhibit the migration of cancer cells and reduce the formation of new blood vessels that feed the tumor.

Biomarker potential

In addition to its potential as a drug target, YGL-1 has also been shown to have potential as a biomarker for cancer. The TGF-β pathway is a well-established biomarker for cancer, and changes in TGF-β signaling have been observed in a wide range of cancer types. By inhibiting the activity of YGL-1, the TGF-β pathway is aberrantly activated in cancer cells, leading to the development of various hallmark changes in cancer cells

Protein Name: MTSS I-BAR Domain Containing 1

Functions: May be related to cancer progression or tumor metastasis in a variety of organ sites, most likely through an interaction with the actin cytoskeleton

The "MTSS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTSS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MTSS2 | MTTP | MTURN | MTUS1 | MTUS1-DT | MTUS2 | MTUS2-AS1 | MTVR2 | MTX1 | MTX2 | MTX3 | mu-Calpain (calpain 1) | MUC1 | MUC12 | MUC13 | MUC15 | MUC16 | MUC17 | MUC19 | MUC2 | MUC20 | MUC20P1 | MUC21 | MUC22 | MUC3A | MUC3B | MUC4 | MUC5AC | MUC5B | MUC6 | MUC7 | MUC8 | Mucin | MUCL1 | MUCL3 | MUL1 | Multisubunit histone acetyltransferase complex | MUPP | MUS81 | Muscarinic Acetylcholine Receptor (mAChR) | MUSK | MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4